Edition:
United States

Spark Therapeutics Inc (ONCE.OQ)

ONCE.OQ on NASDAQ Stock Exchange Global Select Market

81.73USD
12:50pm EDT
Change (% chg)

$5.04 (+6.57%)
Prev Close
$76.69
Open
$75.92
Day's High
$82.88
Day's Low
$75.92
Volume
101,479
Avg. Vol
212,890
52-wk High
$91.75
52-wk Low
$41.06

Select another date:

Tue, May 8 2018

BRIEF-Spark Therapeutics Reports Q1 Loss Per Share Of $1.25

* SPARK THERAPEUTICS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND RECENT BUSINESS PROGRESS

BRIEF-Spark Therapeutics Says Entered Into Asset Purchase Agreement With Jazz Pharmaceuticals Ireland Ltd

* SPARK THERAPEUTICS SAYS ENTERED INTO ASSET PURCHASE AGREEMENT WITH JAZZ PHARMACEUTICALS IRELAND LIMITED - SEC FILING

BRIEF-Children's Hospital Of Philadelphia Foundation To Engage In Dialogue With Spark Therapeutics To Be Allowed To Designate At Least 1 Board Member

* CHILDREN'S HOSPITAL OF PHILADELPHIA FOUNDATION - TO ENGAGE IN DIALOGUE WITH SPARK THERAPEUTICS TO BE ALLOWED TO DESIGNATE AT LEAST 1 BOARD MEMBER

BRIEF-Spark Therapeutics Reports Cash And Cash Equivalents And Marketable Securities Of $540.2 Mln As Of Dec. 31, 2017

* SPARK THERAPEUTICS REPORTS 2017 FINANCIAL RESULTS AND RECENT BUSINESS PROGRESS

Spark licenses blindness gene therapy rights outside U.S. to Novartis

Spark Therapeutics Inc, whose breakthrough gene therapy to treat a rare form of blindness was approved by U.S. regulators in December, said on Wednesday that it had licensed rights to the drug outside the United States to Switzerland-based Novartis AG.

UPDATE 1-Spark licenses blindness gene therapy rights outside U.S. to Novartis

Jan 24 Spark Therapeutics Inc, whose breakthrough gene therapy to treat a rare form of blindness was approved by U.S. regulators in December, said on Wednesday that it had licensed rights to the drug outside the United States to Switzerland-based Novartis AG.

Spark licenses blindness gene therapy rights outside U.S. to Novartis

Jan 24 Spark Therapeutics Inc, whose breakthrough gene therapy to treat a rare form of blindness was approved by U.S. regulators in December, has licensed rights to the drug in markets outside the United States to Switzerland-based Novartis AG, it said on Wednesday.

BRIEF-Spark Therapeutics Enters Into Licensing, Supply Agreement For Investigational Voretigene Neparvovec Outside U.S.

* SPARK THERAPEUTICS ENTERS INTO A LICENSING AND SUPPLY AGREEMENT FOR INVESTIGATIONAL VORETIGENE NEPARVOVEC OUTSIDE THE U.S.

Spark's price for Luxturna blindness gene therapy too high: ICER

The proposed price for Spark Therapeutics Inc's groundbreaking one-time gene therapy for a rare form of blindness is far too high, an independent U.S. nonprofit organization that evaluates clinical and cost effectiveness of new medicines said on Friday.

UPDATE 1-Spark's price for Luxturna blindness gene therapy too high -ICER

Jan 12 The proposed price for Spark Therapeutics Inc's groundbreaking one-time gene therapy for a rare form of blindness is far too high, an independent U.S. nonprofit organization that evaluates clinical and cost effectiveness of new medicines said on Friday.

Select another date: